Kick start day two with clinical case study reviews, group discussion forums, and new updates on the full end-to-end drug development landscape for allogeneic cell therapies.  

Leaders from; AgenTusBone TherapeuticsBristol Myers Squibb and TCR2 will be showcasing: 

  • Novel strategies to overcome safety and tolerability risks 
  • Processes to achieve reproducibility and comparability in manufacture  
  • Experience navigating global regulatory challenges for off-the-shelf production 

… and much more! 

Key speakers include:  

Joe Newell


Atara Biotherapeutics

Peggy Sotiropoulou

Head of Research & Development

Celyad Oncology

Sumiti Jain

Director, Immuno- Oncology, Cell Therapy

Poseida Therapeutics

Tony Ho

EVP, Head of Research & Development

CRISPR Therapeutics

9:30 - 5:05 EDT | 6:30 - 2:05 PDT - All times are shown in EDT

9:30 am Virtual Coffee Networking Rooms

10:00 am Chair’s Opening Remarks

Keynote Clinical Case Studies

10:05 am Realizing the Clinical Potential of CRISPR/Cas9 for Best-in-Class Allogeneic Therapies

  • Tony Ho EVP, Head of Research & Development, CRISPR Therapeutics


• Showcase clinical data from CTX110, CTX120 and CTX130 to review how allogeneic cells function in vivo
• Analayze depth of response, persistence and durability of the allogeneic cells to achieve complete responses
• How do allogeneic cells perform compared to autologous cell therapies?

10:35 am Learnings from Allogeneic CAR-T Clinical Trials

  • Mark Johnson Clinical Translational Scientist, Precision Biosciences


• Discussing patient conditioning without biologic immuno-depletion
• Outlining dosing considerations
• Evaluating cell expansion, persistence, and durability of response

11:05 am How an Effective Source Material Supply Chain Can Enhance Scalability of Cell and Gene Therapies

  • Dominic Clarke Director, Global Cell Therapy Strategy & Innovation, HemaCare


  • Analyzing the impact of source material variability and characterization on downstream efficacy of cell therapy applications
  • Utilizing reliable/recallable and dedicated donor pool strategies to ensure consistency and reproducibility
  • Identifying how cell supply partners can help mitigate risk for clinical translation of allogeneic therapies

11:35 am Differentiated Non-Gene Edited Technologies to Generate Off-The-Shelf CAR-T Cells for the Treatment of Hematopoietic and Solid Malignancies


• Leveraging non-gene edited technologies to disrupt TCR signaling to generate allogeneic CAR T cells
• Exploiting natural receptor/ligand interactions for CAR T cell therapy of metastatic colorectal cancer
• Discussing the first-in-class shRNA-based BCMA-targeting allogeneic CAR T candidate for the treatment of multiple myeloma

12:05 pm Tech Slam – Benchmark Gold-Star Donor Material With Leading Blood Bank Providers


From Clinic to Commercial Reality: Leveraging Transplant Experience to Overcome Cell Therapy Supply Chain Hurdles

Joy Aho, Senior Product Manager, Be The Match BioTherapies

12:15 pm Refreshment Break


Take this time to follow up with your new connections with a 1-1 or group video call or take a break and make a coffee!

2:25 pm Refreshment Break

3.00PM Roundtable Discussion Session

Rob Igarashi, VP, Discovery & Pre-clinical Development, Kiadis Pharma

Christopher Kloss, Assistant Principal Scientist, Cell & Gene Therapy, Merck & Co

Innate Vs. Adaptive Immune Cell Types for Allogeneic Therapy
• Assess the different characteristics of NK, GDT and T cells and how this can impact their success as an allogeneic therapy
• Discuss current clinical and preclinical results, specifically assessing the potential to persist and safety profiles

4:40 pm Closing Remarks

4:45 pm Close of Conference